23andMe to Cut Workforce by 40%, Discontinues Therapeutics Pipeline

@TheWallStreetJournal compartilhou um link

2024-11-12 01:07:34 ·

www.wsj.com

The clinical trials 23andMe intends to wind-down include its two main therapeutic programs. The restructuring is expected to result in expenses of up to $12 million, and savings of more than $35 million per year, 23andMe said.

0 Comentários ·0 Compartilhamentos ·136 Visualizações

Faça Login para curtir, compartilhar e comentar!

Atualize para o Pro

Escolha o Plano que é melhor para você

Atualizar